CDQ yields highest sensitivity and AUC for identifying patients with chronic obstructive pulmonary diseaseNew analysis identifies best tools for detecting COPD symptoms

This systematic review and meta-analysis evaluated the diagnostic performance of various case-finding approaches for chronic obstructive pulmonary disease (COPD). The study included a large population of 70,693 individuals screened for COPD. The analysis compared multiple screening tools including CDQ, CAPTURE, IPAG, PUMA, COPD-PS + PEF, COPD-PS, COPD-SQ, COPD-SQ + PEF, LFQ, CAPT_PEF, and COLA-6 to determine their respective sensitivities, specificities, and area under the curve (AUC) values.

The primary outcomes focused on diagnostic performance metrics. The CDQ tool demonstrated a sensitivity of 0.78 (95% CI 0.70, 0.84), which was identified as the highest sensitivity among all approaches in the direct meta-analysis. Furthermore, the CDQ tool achieved an AUC of 0.76 (95% CI 0.72, 0.79), also representing the highest AUC among all evaluated methods. These results indicate that while several tools are available, the CDQ specifically performs well in identifying positive cases.

Secondary outcomes included SUCRA rankings to provide a comparative hierarchy of performance for sensitivity and specificity. For sensitivity, the ranking was: CDQ (83.9) > CAPTURE (62.3) > IPAG (58.0) > PUMA (52.8) > COPD-PS + PEF (52.3) > COPD-PS (49.1) > COPD-SQ (41.1) > COPD-SQ + PEF (33.6) > LFQ (33.5) > CAPTURE + PEF (24.9) > COLA-6 (8.6). For specificity, the ranking was: COLA-6 (75.8) > COPD-SQ + PEF (75.3) > PUMA (56.7) > CAPTURE + PEF (55.6) > COPD-PS (47.9) > LFQ (42.7) > COPD-PS + PEF (41.7) > COPD-SQ (38.3) > IPAG (33.0) > CDQ (25.7) > CAPTURE (7.3).

Safety and tolerability data were not reported for the various screening tools, as these are diagnostic instruments rather than pharmacological interventions. No adverse events or discontinuations were recorded in the study data.

These results provide a clear distinction between tools based on their primary clinical utility. CDQ, CAPTURE, and IPAG are noted for having high sensitivity, which is critical for ensuring that patients with COPD are not missed during initial screening. Conversely, COLA-6, COPD-SQ + PEF, and PUMA were identified as having higher specificity, which may be more useful in scenarios where minimizing false positives is the clinical priority.

The study notes that further research is required to explore effective COPD screening strategies across different clinical settings. Methodological limitations include the fact that this is a network meta-analysis comparing tool performances rather than a primary clinical trial of interventions. The results indicate an association between specific questionnaire tools and diagnostic performance metrics, but do not establish a causal link.

Clinically, these findings suggest that the choice of screening tool should be dictated by the specific goals of the clinic. For broad population screening where identifying all potential cases is paramount, CDQ may be preferred due to its high sensitivity (0.78). In settings where resources are limited and only highly likely cases should be pursued, tools with higher specificity like COLA-6 or COPD-SQ + PEF may be more appropriate. Questions remain regarding how these tools perform in diverse geographic regions and different clinical environments.